Who are SKLB1028's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sorafenib Standard Dosing Regimen, Sorafenib (SOR), Sorafenib (SORA), Sorafenib Ramp-Up Regimen, TAS-102, Regorafenib , Fruquintinib, Len-TACE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sklb1028.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SKLB1028 — Competitive Intelligence Brief

SKLB1028 (SKLB1028) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-kinase inhibitor. Area: Oncology.

phase 3 Multi-kinase inhibitor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SKLB1028 (SKLB1028) — CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SKLB1028 TARGET	SKLB1028	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	phase 3	Multi-kinase inhibitor
Sorafenib Standard Dosing Regimen	Sorafenib Standard Dosing Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SOR)	Sorafenib (SOR)	The University of Texas Health Science Center at San Antonio	marketed	Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SORA)	Sorafenib (SORA)	Nanfang Hospital, Southern Medical University	marketed	Multi-kinase inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β
Sorafenib Ramp-Up Regimen	Sorafenib Ramp-Up Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
TAS-102, Regorafenib , Fruquintinib	TAS-102, Regorafenib , Fruquintinib	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor	Thymidylate synthase, VEGFR2
Len-TACE	Len-TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor (combined with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-kinase inhibitor class)

University of Florida · 2 drugs in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class
Stephen Chan Lam · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SKLB1028 — Competitive Intelligence Brief. https://druglandscape.com/ci/sklb1028. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab